Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Canelas Vng – page 45

661 clinical trials in Canelas Vng, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Canelas Vng at a glance
661
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

661 trials in Canelas Vng

Open in trial search

Study on Mavacamten for Adults with Non-obstructive Hypertrophic Cardiomyopathy

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten
  • Sponsor:Myokardia Inc.

Study on the Effectiveness and Safety of Nipocalimab for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Myasthenia gravis

Not recruiting

Study on the Safety and Effectiveness of Gefurulimab for Adults with Generalized Myasthenia Gravis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Gefurulimab
  • Sponsor:Alexion Pharmaceuticals Inc.

Study Comparing Asciminib with Other Drug Combinations for Adults with Newly Diagnosed Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

Study on TAR-200 and Cetrelimab for High-Risk Bladder Cancer Patients Not Responding to BCG and Unable or Unwilling to Have Surgery

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Study on Acalabrutinib with Drug Combination for Patients 75 and Older with Untreated Diffuse Large B-Cell Lymphoma

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Study on Vudalimab or Pembrolizumab with Chemotherapy for Advanced Non-small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Xencor Inc.

Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Daiichi Sankyo Inc.

Plasma cell myeloma

Not recruiting

Study Comparing ABBV-383 with Standard Therapies for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Mantle cell lymphoma

Not recruiting

Study of Zanubrutinib and Rituximab Compared to Bendamustine and Rituximab for Patients with Untreated Mantle Cell Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:BeOne Medicines AG

Study Comparing Pirtobrutinib to Bendamustine and Rituximab for Untreated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Loxo Oncology Inc.

Study on Setrusumab for Patients with Osteogenesis Imperfecta (Brittle Bone Disease)

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Setrusumab
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Canelas Vng

What the registry says about research in the country

01 Cardiovascular Research

Clinical investigations focusing on atherosclerotic cardiovascular disease in patients with end-stage kidney disease, exploring innovative therapeutic approaches for this complex patient population.

  • Cardiovascular Outcomes
  • Inflammation Markers
  • Dialysis Patient Care

The research aims to assess treatment effectiveness through monitoring C-reactive protein levels in dialysis patients, potentially leading to improved cardiovascular outcomes in this high-risk group.

02 Nephrology Studies

Specialized research targeting patients with end-stage kidney disease undergoing maintenance dialysis, evaluating novel therapeutic interventions to address cardiovascular complications.

  • Renal Disease Management
  • Dialysis Therapy
  • Cardiovascular Risk

These trials explore intravenous treatments aimed at reducing inflammation markers and improving overall outcomes in dialysis patients.

03 Inflammatory Biomarkers

Investigation of inflammatory markers in cardiovascular disease, specifically focusing on high-sensitivity C-reactive protein as a key indicator in patients undergoing dialysis.

  • Biomarker Analysis
  • Inflammation Control
  • Treatment Response

The research evaluates various dosing strategies to optimize anti-inflammatory responses in patients with combined cardiovascular and kidney conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.